Skip to content

Naloxegol

DRUG20 trials

Sponsors

UZ Leuven, AstraZeneca, Kyowa Kirin Pharmaceutical Development Ltd, Massachusetts General Hospital, Michael Camilleri

Conditions

Brain InjuriesCancerConstipationConstipation Drug InducedConstipation, Signs and Symptoms, DigestiveCritical IllnessDrug Induced ConstipationEsophagus Disorder

Phase 1

Phase 2

Phase 3

Phase 4

Unknown Phase

Naloxegol Drug Utilization Post Authorisation Safety Study
CompletedNCT02813148
Kyowa Kirin Pharmaceutical Development LtdOpioid Induced Constipation
Start: 2015-08-31End: 2020-01-31Updated: 2024-07-23
Naloxegol Health Outcome Post Authorisation Safety Study
TerminatedNCT02813369
Kyowa Kirin Pharmaceutical Development LtdOpioid Induced Constipation
Start: 2016-09-30End: 2021-11-30Updated: 2024-07-23
Naloxegol US PMR CV Safety.
NCT02813356
Valinor Pharma LLCOpioid Induced Constipation
Start: 2016-06-24End: 2023-12-31Target: 8800Updated: 2023-05-15
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
CompletedNCT03638440
Kyowa Kirin Pharmaceutical Development LtdOpioid Induced Constipation
Start: 2018-08-16End: 2020-03-05Updated: 2024-06-17
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
RecruitingNCT03720613
BioDelivery Sciences InternationalOpioid-induced Constipation
Start: 2019-01-04End: 2030-11-01Target: 34532Updated: 2025-02-12
Evaluation of the Quality of Life of Patients With Opioid-induced Constipation Under Treatment With Naloxegol
CompletedNCT04173858
Kyowa Kirin Farmacéutica S.L.U.Opioid-induced Constipation
Start: 2017-09-21End: 2019-10-31Updated: 2019-11-22
Study on Quality of Life in Advanced Cancer Patients With Opioid-induced Constipation Treated With Naloxegol
CompletedNCT04294550
Fondazione ANT Italia ONLUSCancer, Constipation Drug Induced, Opioid Use
Start: 2018-09-01End: 2021-03-31Updated: 2022-02-28

Related Papers